Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for kidney cancer patients whose first treatment stopped working

NCT ID NCT06863311

First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 31 times

Summary

This study tests a new drug called zanzalintinib, alone or with an immunotherapy (nivolumab), in people with advanced kidney cancer that got worse after standard first treatment. About 70 adults will take part. The goal is to see if the combination can shrink tumors or slow the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Columbia University Irving Medical Center

    RECRUITING

    New York, New York, 10032, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    RECRUITING

    Indianapolis, Indiana, 46202, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California San Diego

    RECRUITING

    La Jolla, California, 92093, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.